Arrowhead Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARWR | IONS | ALNY | 4591.T | 688382.SS | ADRX | |
|---|---|---|---|---|---|---|
| Market cap | 8.71B | 6.67B | 21.57B | 3.39B | 8.38B | 1.66B |
| P/E (TTM) | — | — | 8.1 | — | — | — |
| Forward P/E | -12.4 | -35.0 | 14.4 | -1.1 | -43.8 | -9.9 |
| Price/book | 18.7 | 15.1 | 6.0 | 1.2 | 6.6 | -0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +47.68% | −45.88% | −63.21% | −29.21% | −48.70% | −16.85% |
| Today | +3.56% | −0.67% | +0.74% | −4.76% | +4.33% | −7.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All ARWR news ›Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
BioSpace Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday,…
Frontiers Retracts Rat Study on Grape Pomace Extract Taurisolo Over Image Integrity Concerns
Frontiers in Cellular Neuroscience has retracted a 2020 rat study claiming the grape pomace extract Taurisolo protects the brain from ischemia-reperfusion injury after an investigation into the integrity of the published figures left the…
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and CRISPR Therapeutics (NASDAQ:CRSP) Financial Review
Posted by Sarita Garza on Oct 26th, 2026 CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both mid-cap healthcare companies, but which is the superior business? We will…
Institute for Molecular Medicine and Nuravax Announce First Participants Dosed in Phase 1 TAURUS-1980 Study of AV-1980R
Oct 07, 2026, 08:00 ET Groundbreaking randomized study will evaluate safety, tolerability, and immune responses to the investigational preventive tau vaccine in up to 48 cognitively unimpaired individuals with confirmed brain amyloid…
Resolve Therapeutics Presents Preclinical Data on NET Degradation and Nuclease Therapy in Acute Ischemic Stroke at the World Stroke Conference
Oct 21, 2026, 09:55 ET ePoster #2338 - In vitro NET degradation and inhibition. In experiments using neutrophils from healthy donors: Taken together, the NET and stroke-model findings strengthen the rationale for advancing RSLV-132 and…
Scientists find a way to fight Alzheimer’s brain damage without removing toxic tau
The results were striking. Compared with untreated mice, animals receiving the antibody retained roughly 40% more tissue in brain regions involved in memory and performed better on a memory test. These improvements occurred even though the…
Arrowhead’s Alzheimer’s Drug Shows Sharp Reduction In Disease-Linked Protein In Early Trial – Here’s What Investors Need To Know
Arrowhead Pharmaceuticals (ARWR) was on investors’ radar on Wednesday, after the biotech firm reported strong early results for its experimental Alzheimer’s disease treatment, ARO-MAPT, which significantly reduced levels of a protein…
UBS Group Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “Strong-Buy”
Posted by Kim Johansen on Oct 17th, 2026 Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports. View Our Latest…
Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head Review
Posted by Danessa Lincoln on Oct 18th, 2026 Sera Prognostics (NASDAQ:SERA – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- seekingalpha.com4
- themarketsdaily.com3
- ir.arrowheadpharma.com2
- stocktitan.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 30 articles, not a forecast.